Search research articles
Contact Us
Filters
Showing results (1-10 of 233) with videos related to
Page
of 24
Sort By:
Neurology
|
August 3, 2012
Caffeine in Parkinson disease: better for cruise control than snooze patrol?
Michael A Schwarzschild
The New England Journal of Medicine
|
February 27, 2010
Rasagiline in Parkinson's disease
Michael A Schwarzschild
Journal of Parkinson'S Disease
|
December 31, 2016
Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
Michael A Schwarzschild
Neurology
|
November 25, 2010
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
Michael A Schwarzschild
Progress in Neurobiology
|
November 13, 2007
Adenosine A2A antagonists as neurotherapeutics: crossing the bridge
Michael A Schwarzschild
Brain Research
|
April 1, 2014
Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease
Anil Kachroo, Michael A Schwarzschild
Science'S STKE : Signal Transduction Knowledge Environment
|
January 16, 2003
DARPP chocolate: a caffeinated morsel of striatal signaling
Elena Bastia, Michael A Schwarzschild
The Lancet. Neurology
|
October 19, 2016
The epidemiology of Parkinson's disease: risk factors and prevention
Alberto Ascherio, Michael A Schwarzschild
Annals of Neurology
|
February 28, 2012
Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease
Anil Kachroo, Michael A Schwarzschild
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
December 21, 2016
Urate as a Marker of Risk and Progression of Neurodegenerative Disease
Sabrina Paganoni, Michael A Schwarzschild
Page
of 24
Search research articles
Search
Showing results (1-10 of 233) with videos related to
Sort By:
Page
of 24
Neurology
|
August 3, 2012
Caffeine in Parkinson disease: better for cruise control than snooze patrol?
Michael A Schwarzschild
The New England Journal of Medicine
|
February 27, 2010
Rasagiline in Parkinson's disease
Michael A Schwarzschild
Journal of Parkinson'S Disease
|
December 31, 2016
Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
Michael A Schwarzschild
Neurology
|
November 25, 2010
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
Michael A Schwarzschild
Progress in Neurobiology
|
November 13, 2007
Adenosine A2A antagonists as neurotherapeutics: crossing the bridge
Michael A Schwarzschild
Brain Research
|
April 1, 2014
Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease
Anil Kachroo, Michael A Schwarzschild
Science'S STKE : Signal Transduction Knowledge Environment
|
January 16, 2003
DARPP chocolate: a caffeinated morsel of striatal signaling
Elena Bastia, Michael A Schwarzschild
The Lancet. Neurology
|
October 19, 2016
The epidemiology of Parkinson's disease: risk factors and prevention
Alberto Ascherio, Michael A Schwarzschild
Annals of Neurology
|
February 28, 2012
Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease
Anil Kachroo, Michael A Schwarzschild
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
December 21, 2016
Urate as a Marker of Risk and Progression of Neurodegenerative Disease
Sabrina Paganoni, Michael A Schwarzschild
Page
of 24